Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

NCT00560313 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease

Interventions

BIOLOGICAL: Men ACWY CRM
BIOLOGICAL: 4CMenB

Sponsor

Novartis Vaccines